文献速递消化道肿瘤放疗

现代高剂量对比标准剂量放疗在食管鳞癌根治性同步放化疗中的疗效:Meta分析

Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer: a meta-analysis.
PubMed 文献 · Radiat Oncol · 2019-10-17

该系统评价与Meta分析纳入1990至2018年间8项研究共3736例食管癌患者,比较现代放疗技术下高剂量(≥60 Gy)与标准剂量放疗在根治性同步放化疗中的疗效。结果显示高剂量放疗在总生存、无进展生存和局部区域无复发生存方面均显著优于标准剂量。

要点

  • 高剂量(≥60 Gy)放疗显著改善总生存(HR=0.78,95%CI 0.72-0.84)。
  • 高剂量放疗显著改善局部区域无复发生存(HR=0.52,95%CI 0.36-0.74)。

核心结论

  • 基于现代放疗技术的根治性同步放化疗中,高剂量(≥60 Gy)较标准剂量可改善食管鳞癌患者的总生存、无进展生存和局部区域无复发生存。

研究设计与样本

  • 最终纳入8篇文章共3736例患者,采用RevMan 5.3以风险比(HR)评估时间事件数据。

主要发现

  • 高剂量放疗组总生存显著获益(HR=0.78,95%CI 0.72-0.84,p<0.001;2年OS风险比RR=1.25,95%CI 1.14-1.37,p<0.001)。
  • 高剂量放疗组局部区域无复发生存显著获益(P<0.001,HR=0.52,95%CI 0.36-0.74)。

关键数值与推荐

  • 高剂量放疗定义为≥60 Gy,对照为标准剂量放疗,均用于根治性同步放化疗。

临床怎么用

  • 对接受根治性同步放化疗的食管鳞癌患者,可考虑采用现代放疗技术给予≥60 Gy的高剂量放疗以改善生存和局部控制。

局限性

  • 纳入研究多为回顾性,证据级别受限于原始研究设计。
  • 未报告高剂量放疗的具体毒性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Radiation Therapy Oncology Group (RTOG) 94-05 has demonstrated that higher dose radiation didn't improve outcome of patients with esophageal cancer (EC). However, several retrospective studies showed that a higher dose radiation based on modern radiotherapy techniques could improve overall survival (OS) and local control rate (LCR) of patients with EC, especially esophageal squamous cell cancer (ESCC). As trials have provided updated and controversial data, we performed this updated meta-analysis to investigate whether high-dose (> = 60 Gy) radiotherapy in definitive concurrent chemo-radiotherapy (CCRT) could yield benefit compared to standard dose radiotherapy. METHODS: A systematic literature search was carried out in the database of MEDLINE, PubMed and Embase. All studies published between 1 January 1990 and 31 December 2018 on the association between radiation dose and curative efficiency in EC were included in this meta-analysis. The hazard ratio (HR) was used to evaluate the time-to-event data employing RevMan version 5.3. RESULTS: Eight articles with a total of 3736 patients were finally included. Results indicated that there was a significant benefit in favor of high dose radiotherapy (HD-RT) regarding OS (HR = 0.78, 95%CI: 0.72-0.84, p < 0.001; 2-year OS risk ratio (RR) = 1.25, 95%CI: 1.14-1.37, p < 0.001), progression-free survival (PFS) (P = 0.001, HR = 0.7, 95%CI: 0.57-0.87) and LRFS (P < 0.001, HR = 0.52, 95%CI: 0.36-0.74) . CONCLUSIONS: HD-RT (> = 60 Gy) based on modern radiotherapy techniques in definitive CCRT appears to improve OS, PFS amd LRFS compared to the SD-RT in patients with ESCC.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Luo HS, Huang HC, Lin LX, et al. Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer: a meta-analysis. Radiat Oncol. 2019. PMID: 31623639. doi:10.1186/s13014-019-1386-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。